Pedro Barata, MD
Hematology & Oncology · New Orleans, LANPI 1841746542
Payments from drug & device makers
Across 1,142 payments — averaging $3721.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$1.2M
- Janssen Research & Development, LLC$921K
- Merck$558K
- Pfizer$388K
- AVEO Pharmaceuticals, Inc.$291K
- AstraZeneca$151K
- plus $692K from 31 others
Across 18 payments — averaging $1100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 150 | $1,249,123 |
| Janssen Research & Development, LLC | 28 | $920,627 |
| Merck | 57 | $557,818 |
| Pfizer | 135 | $387,622 |
| AVEO Pharmaceuticals, Inc. | 212 | $291,149 |
| AstraZeneca | 77 | $150,768 |
| Seagen Inc. | 35 | $126,564 |
| Astellas Pharma US Inc | 104 | $114,730 |
| Sumitomo Pharma America, Inc. | 17 | $103,578 |
| Bayer | 80 | $98,142 |
| Blue Earth Diagnostics | 11 | $68,062 |
| Sanofi | 23 | $40,718 |
| EMD Serono, Inc. | 29 | $37,295 |
| Ipsen Innovation | 4 | $18,202 |
| Telix Pharmaceuticals | 38 | $17,885 |
| Genentech, Inc. | 9 | $15,708 |
| E.r. Squibb & Sons, L.L.C. | 22 | $13,404 |
| Eisai Inc. | 24 | $11,868 |
| Johnson & Johnson | 8 | $7,178 |
| Janssen Scientific Affairs, LLC | 7 | $4,388 |
| Astellas Pharma Europe Ltd | 2 | $3,570 |
| Dendreon Pharmaceuticals LLC | 16 | $3,057 |
| Myovant Sciences Inc. | 8 | $2,788 |
| Ipsen Pharma SAS | 1 | $1,740 |
| Astrazeneca UK Limited | 12 | $1,439 |
| Sanofi-aventis U.S. LLC | 5 | $435 |
| Caris MPI, Inc. | 8 | $379 |
| Novartis | 5 | $361 |
| Clovis Oncology, Inc. | 3 | $279 |
| Gilead | 3 | $155 |
| Roche Diagnostics Corporation | 1 | $113 |
| Lilly USA, LLC | 2 | $108 |
| Regeneron Healthcare Solutions, Inc. | 1 | $100 |
| Boston Scientific | 2 | $97 |
| Coherus Oncology, Inc. | 1 | $94 |
| Astellas Pharma Global Development | 1 | $33 |
| Amgen | 1 | $24 |
How this compares
$4,249,603 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New Orleans
- Marc MatranaNew Orleans$4.6M
- Carter DavisNew Orleans$1.6M
- Maissaa JanbainNew Orleans$1.5M
- Lingling duNew Orleans$1.2M
- John ColeNew Orleans$896K
- Cindy LeissingerNew Orleans$432K
- Furhan YunusNew Orleans$422K
- David MorrisonNew Orleans$313K
- Stefan GrantNew Orleans$261K
- Michelle LochNew Orleans$232K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.